Wednesday, 1 September 2021

Utility of Mucositis Predictive Tools in Patients Receiving Chemo Radiotherapy for Various Indications

Mucositis is a distressing and common consequence in Chemo radiation patients, with varied incidence and severity. In diverse patient populations, certain clinical variables are linked to the occurrence and severity of mucositis. Early prediction techniques based on such clinical characteristics may aid clinicians in implementing a variety of preventative interventions in high-risk patients.

To see how effective two distinct technologies are at predicting different types of mucositis.

Methods- From January 2019 to November 2020, we conducted a prospective observational (non-interventional) study with 438 patients, who were followed up to April 2021 using two published techniques for predicting the severity of mucositis. The population comprises of patients with head and neck squamous cell cancer who have been allocated to receive chemoradiotherapy and who have been divided into three risk groups using the techniques mentioned above: low, intermediate, and high. They were followed up on to see if they developed mucositis and how severe it was.

Identifying high-risk patients prior to the start of chemoradiotherapy for the purpose of predicting mucositis can assist clinicians in taking strict preventive measures to avoid or reduce the severity of the serious adverse effect, thereby improving the quality of life and avoiding treatment interruption.




 

Tuesday, 24 August 2021

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia

 For the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), an uncommon adverse effect of adenoviral vector vaccinations against coronavirus illness, high-dose intravenous immune globulin (IVIG) plus anticoagulation is advised (Covid-19). The response to IVIG therapy in three of the first patients with VITT in Canada after receiving the ChAdOx1 nCoV-19 vaccination is described. The patients ranged in age from 63 to 72 years old, with one being a woman. Canada had restricted the use of the ChAdOx1 nCoV-19 vaccine to people 55 and older at the time of this publication, based on concerns that VITT had occurred largely in younger people. Two of the patients in our study had limb-artery thrombosis, while the third had venous and arterial thrombosis in the brain. In response to heparin and platelet factor 4 (PF4), different patterns of serum-induced platelet activation were detected, showing the variety of VITT manifestations in serum. All three individuals had lower antibody-induced platelet activation in serum after starting IVIG. 




Friday, 13 August 2021

Role of Tetraspanins in Hepatocellular Carcinoma

 

Hepatocellular carcinoma (HCC) has a high incidence, morbidity, and fatality rate. Liver cancer is the sixth most frequent cancer in the world, with HCC accounting for over 80% of cases. HCC advances quickly, and there is currently no cure for advanced HCC. Tetraspanins are a type of protein that has four transmembrane domains. 33 tetraspanins are found on the surface of most nucleated cells and are involved in a variety of biological processes. 



In this study, we outline the roles of tetraspanins and their underlying mechanisms throughout the HCC life cycle, from start to progression to therapy. CD9, TSPAN15, and TSPAN31 are all known to increase HCC cell proliferation while also decreasing apoptosis. CD63, CD151, and TSPAN8 may help HCC spread in some way, while CD82 acts as a metastasis suppressor. TSPAN1, TSPAN8, and CD151 are prognostic indicators that have been shown to be inversely linked with HCC patients' overall survival rates. We also highlight the tetraspanin family's potential as a novel therapeutic target and a solution to drug resistance, as well as various research directions.


Friday, 30 July 2021

34th Conference on Preventive Oncology & Diagnostic Cancer

Preventive Oncology 2021 invites everyone to attend the "34th conference on preventive Oncology and Diagnostic Cancer," which will be held on October 22-23, 2021 | Webinar.

The purpose of Preventive Oncology 2021 is to provide a revolutionary professional evolution experience that encompasses the full scope of contemporary oncology research and the implementation of emerging technologies for cancer therapy. The major goal of the conference is to gather well-known oncologists together; cancer internet visitors include researchers, academics, and business leaders who are interested in this topic, students, and business delegates in a location where they may exchange their knowledge and scientific advancements in the field of oncology and cancer therapy, influencing future research.

The speakers at this conference are well-known and knowledgeable, and they will cover both broad and specific themes of interest. Our conference's main goals are to provide oncology physicians, specialists, nurses, techs, and anybody else working in the field with an opportunity to learn about the disease's evolution discuss interventional techniques, gain an understanding of new and advanced cancer treatment practices, as well as their efficiency and efficacy in the treatment of varied situations, and gain an understanding of local realities and practical restrictions in enhancing patient care.

Utility of Mucositis Predictive Tools in Patients Receiving Chemo Radiotherapy for Various Indications

Mucositis is a distressing and common consequence in Chemo radiation patients, with varied incidence and severity. In diverse patient popula...